Table 2.

ASM doses among groups.

		CYP and P-GP group	P-GP group	Control group
	Total N	43	13	264
ASM daily dose (median, N, IQR)	LEV	1,000 [15 (35%), 1,000–1,975]	1, 000 [13 (100%), 1,000–1,600]
	VPA	1,300 [26 (60%), 1,000–1,500]
	PHT	300 [17 (40%), 300–300]
	LMT	275 [3 (7%), 212.5–337.5]
	TPM	600 [1 (2%)]
	CBZ	800 [2 (5%), 800–800]
	ZNS	500 [2 (5%), 500–500]
	PER	2 [6 (14%), 2–4]	2 [1 (8%)]	2 [9 (3%), 2–4]
	LCS	300 [4 (9%), 200–400]	200 [2 (15%), 200–200]	200 [10 (4%), 200–200]

ASM, anti-seizure medication; IQR, interquartile range; N, number; NOAC, non-vitamin K oral anticoagulant; CYP, cytochrome P450 3A4; P-GP, permeability glycoprotein; LEV, levetiracetam; VPA, valproic acid; PHT, phenytoin; TPM, topiramate; LMT, lamotrigine; CBZ, carbamazepine; ZNS, zonisamide; PER, perampanel; LCS, lacosamide.